White-Matter Astrocytes,Axonal Energy Metabolism,and Axonal Degeneration in Multiple Sclerosis

Abstract

In patients with multiple sclerosis (MS), a diffuse axonal degeneration occurring throughout the white matter of the central nervous system causes progressive neurologic disability. The underlying mechanism is unclear. This review describes a number of pathways by which dysfunctional astrocytes in MS might lead to axonal degeneration. White-matter astrocytes in MS show a reduced metabolism of adenosine triphosphate-generating phosphocreatine, which may impair the astrocytic sodium potassium pump and lead to a reduced sodium-dependent glutamate uptake. Astrocytes in MS white matter appear to be deficient in β₂ adrenergic receptors, which are involved in stimulating glycogenolysis and suppressing inducible nitric oxide synthase (NOS2). Glutamate toxicity, reduced astrocytic glycogenolysis leading to reduced lactate and glutamine production, and enhanced nitric oxide (NO) levels may all impair axonal mitochondrial metabolism, leading to axonal degeneration. In addition, glutamate-mediated oligodendrocyte damage and impaired myelination caused by a decreased production of N-acetylaspartate by axonal mitochondria might also contribute to axonal loss. White-matter astrocytes may be considered as a potential target for neuroprotective MS therapies.

Keywords

astrocytes axonal degeneration energy metabolism multiple sclerosis

The majority of patients with multiple sclerosis (MS) begin with a relapsing-remitting course, which often after several years of disease duration converts into a progressive disease (secondary progressive MS). In a minority of patients, progressive neurologic deterioration without remission occurs from the disease onset (primary progressive MS). Multiple sclerosis is traditionally viewed as a T cell-driven autoimmune disease against myelin of the central nervous system (Compston and Coles, 2008). Substantial evidence indicates that inflammation has a key role in the development of focal demyelinating lesions that constitute the pathological substrate for relapses. However, the progressive phase of MS reflects a poorly understood insidious axonal degeneration that is age related and independent of relapses (Confavreux and Vukusic, 2006; Koch et al, 2007a). Pathological studies have shown that axonal degeneration occurs diffusely throughout the normal appearing white matter (Evangelou et al, 2000). This neurodegenerative component is associated with inflammation (Frischer et al, 2009), but there is growing awareness that inflammatory mechanisms alone cannot explain this degenerative process. Immunomodulatory drugs, which reduce the development of focal lesions and relapses, are not effective in progressive MS (Wilkins and Scolding, 2008), and pathological studies show ongoing demyelination and axonal degeneration despite pronounced immunosuppression (Metz et al, 2007).

Axonal degeneration might be caused by Wallerian degeneration secondary to axonal injury in focal demyelinating lesions (Ferguson et al, 1997; Trapp et al, 1998). However, both magnetic resonance imaging and neuropathological studies found a lack of correlation between focal lesion load and axonal loss in the spinal cord (Bergers et al, 2002; DeLuca et al, 2006; Kutzelnigg et al, 2005), indicating that mechanisms other than Wallerian degeneration contribute to this progressive axonal degeneration.

A current hypothesis suggests that axonal mitochondrial energy failure may lead to axonal degeneration in MS (Su et al, 2009; Trapp and Stys, 2009). There is an increasing awareness that astrocytes have an important role in a variety of neurodegenerative diseases (De Keyser et al, 2008; Kimelberg and Nedergaard, 2010; Ransom et al, 2003), but their possible role in the pathogenesis of MS has received little attention. This review describes a number of pathways by which dysfunctional white-matter astrocytes in MS might lead to axonal mitochondrial energy failure and axonal degeneration.

Phosphocreatine metabolism

Phosphorus magnetic resonance spectroscopy of the brain produces multiple peaks representing high-energy phosphorus compounds, including phosphocreatine (PCr) and adenosine triphosphate (ATP). Minderhoud et al (1992) found that compared with healthy controls, MS patients had increased PCr/β-ATP ratios in the centrum semiovale, and this correlated with clinical measures of MS severity. The β-ATP peak does not contain contributions from other components and appears to be constant under different metabolic conditions (van der Knaap and Pouwels, 2005), suggesting that PCr levels were elevated. Husted et al (1994) found significantly increased PCr/total ³¹P ratio values in the normal appearing white matter of the centrum semiovale, but not in focal MS lesions of MS patients versus healthy controls. Steen et al (2010) corroborated these findings by detecting significantly increased PCr/β-ATP and PCr/total ³¹P ratios in the normal appearing white matter of the centrum semiovale of MS patients, compared with healthy controls.

The results from these three independent studies indicate that PCr levels in the normal appearing white matter of MS patients are increased, suggesting that this source of energy generated by mitochondrial creatine kinase (CK) is not properly used.

Phosphocreatine acts as a metabolic buffer that is transported from mitochondria to high-energy consuming areas in the cytosol (Figure 1A). Cytosolic CK catalyzes the reversible transfer of the phosphor group from PCr to ADP, generating ATP at a much faster rate than glycolysis and oxidative phosphorylation (Brosnan and Brosnan, 2007). The brain cytosolic CK isoform is CK-BB, which in white matter appears to be exclusively present in astrocytes in both rat and human brain (Tachikawa et al, 2004; Thompson et al, 1980).

Figure 1

(A) Schematic representation of the astrocyte phosphocreatine (PCr)–creatine (Cr) cycle. Mitochondrial creatine kinase (CK) ensures that adenosine triphosphate (ATP), produced by oxidative phosphorylation, is converted into PCr. Phosphocreatine diffuses to the thin astrocytic processes where it is metabolized to Cr by CK-BB to generate ATP. The expression of CK-BB is stimulated by cAMP (this has been showed in a human astrocytoma cell line and needs confirmation in astrocytes). The propagation of action potentials along axons leads not only to the expulsion of K⁺ but also to rapid vesicular release into the extracellular fluid of glutamate. The most ATP consuming activity in the astrocytic end feet is the Na⁺/K⁺-ATP pump. It takes up K⁺ released by axons after each depolarization, and it establishes the Na⁺ gradient necessary for glutamate uptake by the astrocytic Na⁺-dependent glutamate transporters. (B) In multiple sclerosis (MS), CK-BB levels and activity are reduced by free radicals and/or decreased transcription due to reduced cAMP formation secondary to a loss of astrocytic β₂ adrenergic receptors. As a consequence, PCr is not properly metabolized, leading to failure of the Na⁺/K⁺-ATP pump and reversal of glutamate uptake by the glutamate transporters. Enhanced glutamate levels in the extracellular space surrounding axons may overactivate axonal α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionic acid (AMPA)/kainate receptors and lead to glutamate-mediated axonal degeneration. Oligodendrocytes, which express AMPA and N-methyl-d-aspartate (NMDA) receptors, are also sensitive to excitotoxic damage. EAAT, Excitatory Amino Acid Transporter.

N-acetylaspartate (NAA) is an amino acid that is primarily localized to neurons and their axons, where it is synthesized by mitochondria (Bates et al, 1996; Moffett et al, 2007; Patel and Clark, 1979). There was no correlation between the decreased NAA/Cr ratio and the increased PCr/β-ATP and PCr/total ³¹P ratios, suggesting that the reduced astrocytic PCr metabolism in the normal appearing white matter of MS subjects is not secondary to a decreased axonal energy metabolism or axonal loss (Steen et al, 2010). Compared with controls without central nervous system disease, significantly reduced levels and activity of CK-BB were found in postmortem normal appearing white-matter brain samples in patients with progressive MS, which might provide an explanation for the elevated PCr levels (Steen et al, 2010; Figure 1B).

Mechanisms that may lead to a decreased CK-BB concentration in cerebral white matter are a reduced transcription or posttranslational modification of the enzyme. Decreased transcription might be caused by a deficiency of astrocytic β₂ adrenergic receptors in MS white matter (De Keyser et al, 1999; Zeinstra et al, 2000). Activation of these receptors by norepinephrine increases the levels of intracellular cAMP. Norepinephrine, activating these β₂ adrenergic receptors, is probably released from axonal varicosities that are present along noradrenergic axons throughout the white matter (Chiti and Teschemacher, 2007). Reduction of intracellular cAMP levels impairs the transcription of CK-BB in cultured human U87-MG glioblastoma cells (Kuzhikandathil and Molloy, 1994, 1999).

The mechanism underlying a loss of β₂ adrenergic receptors on astrocytes in MS is unclear. The same finding has been made in dogs following an encephalomyelitis caused by the canine distemper morbillivirus. This condition leads to a chronic demyelinating disease that is very similar to MS, including an axonal degeneration throughout the normal appearing white matter (Seehusen and Baumgartner, 2010; Vandevelde and Zurbriggen, 2005). Although an infectious component has long been suspected, no specific transmissible agent has so far been linked convincingly to MS. Searches for the presence of a morbillivirus in postmortem MS brain tissue have been inconclusive (Geeraedts et al, 2004; Lassmann et al, 2003).

Posttranslational modification of CK-BB might be caused by free radicals, especially by the oxidation of thiol groups of its structure (Wolosker et al, 1996). There are indications that posttranslational oxidative modification of the enzyme may contribute to decreased CK-BB activity in the cerebral cortex in a number of neurodegenerative disorders, including Alzheimer's disease (Aksenov et al, 2000; Aksenov et al, 1999). In MS, there is increased production of reactive oxygen species, not only in focal inflammatory white-matter lesions (Langemann et al, 1992), but also throughout the normal appearing white matter (Graumann et al, 2003). Further research is needed to find out which mechanism is primarily involved.

Possible consequences of an impaired phosphocreatine metabolism

The most ATP consuming activity in astrocytic end feet during axonal electrogenesis is the Na⁺/K⁺-ATP pump. It takes up K⁺ released by axons in the extracellular space after each depolarization, and it establishes the Na⁺ gradient necessary for glutamate uptake by the astrocytic Na⁺-dependent glutamate transporters (Figure 1A; Anderson and Swanson, 2000; Danbolt, 2001). Axonal release of glutamate is thought to represent a widespread mechanism for activity-dependent signaling at the axon—glia interface throughout the white matter. Glutamate in white-matter axons is stored in vesicles, and the propagation of action potentials along these axons leads to rapid vesicular release of glutamate into the extracellular fluid by exocytosis (Kukley et al, 2007; Ziskin et al, 2007). White-matter axons contain voltage-gated Ca²⁺ channels and the vesicle fusion machinery that are necessary for this type of activity-mediated exocytosis (Alix and Domingues, 2011). The functional significance of this vesicular glutamate release is unclear. After stimulation of white-matter axons, synaptic-like potentials mediated by α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionic acid (AMPA) receptors have been recorded in patch-clamped NG2+ glia (Kukley et al, 2007).

In human white matter, the Excitatory Amino Acid Transporter 1 is expressed in oligodendrocytes and astrocytes, whereas Excitatory Amino Acid Transporter 2, which has the largest role in regulating extracellular glutamate concentration, is essentially located throughout the processes of astrocytes (Domercq and Matute, 1999; Vallejo-Illarramendi et al, 2006). These transporters move glutamate into astrocytes and oligodendrocytes against a steep concentration gradient by coupling glutamate translocation to the transmembrane Na⁺, K⁺ gradients. These gradients are maintained by the membrane Na⁺/K⁺-ATP pump, such that glutamate uptake is ultimately ATP dependent.

Reduced activity of the astrocytic Na⁺/K⁺-ATP pump will lead to high extracellular K⁺ concentrations and reversal of glutamate uptake by glutamate transporters (Figure 1B; Rose et al, 2009). Peripheral astrocytic processes containing mitochondria (Lovatt et al, 2007) terminate as fine astrocytic endings that contact the axonal nodes (Raine, 1984). There is evidence from in-vitro studies that PCr, which is transported from the mitochondria, contributes as an energy source in the distal astrocytic processes, which contain glutamate transporters (Reichenbach et al, 2010). Inhibition of the Na⁺/K⁺ pump in astrocyte cultures by ouabain decreases energy expenditure, and led to a raise in PCr levels (Silver and Erecinska, 1997). However, a glutamate challenge to cultured astrocytes, requiring enhanced glutamate uptake, was associated with enhanced PCr consumption (Fonseca et al, 2005; Sonnewald et al, 1997). The addition of the glutamine synthetase inhibitor methionine sulfoximine had no effect on the PCr concentrations, suggesting that Na⁺/K⁺ pump activity was involved (Sonnewald et al, 1997).

Compared with healthy controls, subjects with MS have increased glutamate levels throughout the normal appearing white matter (Srinivasan et al, 2005), and in the cerebrospinal fluid (Sarchielli et al, 2003). Central myelinated axons express functional kainate and Ca²⁺ permeable AMPA receptors, which on overstimulation by glutamate may lead to excitotoxic damage of axons, caused by an increased influx of Ca²⁺(Ouardouz et al, 2009a, 2009b).

Oligodendrocytes, expressing AMPA/kainate and N-methyl-d-aspartatereceptors, are also sensitive to glutamate toxicity, which is associated with caspase-3 activation, DNA fragmentation, apoptotic cell death, and demyelination (Domercq et al, 2005; Karadottir and Attwell, 2007; Salter and Fern, 2005; Xu et al, 2008). Damage of the myelin sheath itself may contribute to axonal degeneration by reducing trophic support to axons and impairing axonal transport (Nave, 2010). Irvine and Blakemore (2008) elegantly showed that myelin loss contributes to the axon loss, and that remyelination can protect against axonal loss. They inhibited remyelination in the cuprizone model by exposing the brain to X-irradiation before cuprizone intoxication. This resulted in a significant increase in the extent of axonal degeneration and loss compared with nonirradiated cuprizone-fed mice. Restoring the remyelinating capacity in these X-irradiated mice, by transplanting embryo-derived neural progenitors, resulted in a significant increase in axon survival compared with nontransplanted X-irradiated cuprizone-intoxicated mice.

Axonal energy metabolism

Axonal mitochondrial ATP metabolism and the synthesis of NAA are indirectly linked (Figure 2). Aspartate aminotransferase facilitates the conversion of glutamate to α-ketoglutarate and oxaloacetate to aspartate. Glutamate in neurons and their axons is mainly derived from glutamine that is shuttled from astrocytes to neurons, because pyruvate carboxylase is a glia-specific enzyme (Hertz et al, 2007). Pyruvate kinase converts pyruvate to oxaloacetate. After condensation of oxaloacetate with acetyl CoA, the resulting citrate molecule can be converted to α-ketoglutarate and subsequently to glutamine. There are some indications that carboxylation of pyruvate, supporting the formation of glutamate, may also occur in neurons, but the mechanism is not clear (Fan et al, 2010; Hassel, 2001). Acetylation of aspartate by the neuronal enzyme aspartate N-acetyltransferase results in the formation of NAA that is exported from mitochondria. The formation of NAA thereby favors the conversion of glutamate to α-ketoglutarate, which is a mechanism in neurons to bypass the slower citrate synthase reaction in the tricarboxylic acid cycle (Yudkoff et al, 1994). The levels of NAA in normal appearing white matter, as measured by ¹H magnetic resonance spectroscopy, are thus considered to be both a marker of axonal mitochondrial function and axonal integrity.

Figure 2

Schematic representation of the possible mechanism underlying N-acetylaspartate (NAA) synthesis by axonal mitochondria. The dashed lines indicate the part of the tricarboxylic acid cycle in neurons that can be bypassed by the conversion of glutamate and oxaloacetate to α-ketoglutarate and aspartate via the enzyme aspartate aminotransferase (AAT). Glutamine is synthetized in astrocytes, released in the extracellular space and taken up by the axons. Acetylation of aspartate by aspartate N-acetyltransferase (asp-N-AT) leads to the formation of NAA, which is removed from neuronal mitochondria, thereby favoring the conversion of glutamate to α-ketoglutarate, which can enter the truncated tricarboxylic acid cycle for adenosine triphosphate (ATP) production.

Several ¹H magnetic resonance spectroscopy studies of the normal appearing white matter in MS subjects showed decreased levels of NAA compared with healthy controls (Aboul-Enein et al, 2010; Chard et al, 2002; De Stefano et al, 1998, 2001, 2002; Fu et al, 1998; Leary et al, 1999; Lee et al, 2000). Decreased NAA levels in normal appearing white matter are already present at the early stages of the disease and progresses over time (De Stefano et al, 2001). Cader et al (2007) investigated the relationship between callosal size, diffusion magnetic resonance imaging parameters, and NAA concentrations in the corpus callosum in MS patients. Relative changes in NAA were not directly related to diffusion-derived parameters of axonal loss. Another study in MS patients estimated the structural contributions to NAA, as assessed by axial diffusivity derived from diffusion tensor imaging and cross-sectional volumetric imaging in the spinal cord (Ciccarelli et al, 2010b). Lower residual variance in NAA, reflecting information specific to axonal mitochondrial metabolism, was associated with greater clinical disability independent of structural damage. These findings support the idea that metabolic mitochondrial dysfunction in axons, and not just axonal loss, is an important determinant of reduced NAA concentrations in the normal appearing white matter of MS patients.

Reductions of NAA in normal appearing white matter of drug naive MS subjects were partially reversible in a 2-year longitudinal assessment in the early stages of relapsing-remitting MS (Tiberio et al, 2006). Only 30% of the patients in this study started with interferon β during the evaluation period. Spontaneous recovery of NAA concentrations in focal lesion has also been documented in brain and spinal cord of MS patients (Ciccarelli et al, 2010a; Davie et al, 1994). These spontaneous improvements may reflect either restored mitochondrial activity or a compensatory increase in the number of mitochondria. Histopathological studies found increased numbers of mitochondria and an upregulation of mitochondrial cytochrome C oxidase (complex IV) in axons in both chronic lesions and normal appearing white matter of MS subjects (Mahad et al, 2009; Witte et al, 2009).

An increase in NAA levels in normal appearing white matter of relapsing-remitting MS subjects has been reported after 2 years of treatment with glatiramer acetate (Khan et al, 2005), and after 1 year of treatment with β-interferon (Narayanan et al, 2001). However, numbers of patients in these studies were low, and spontaneous improvement as observed in early onset MS could not be excluded. Another study found no effect of 1-year treatment with β-interferon on white-matter NAA levels in relapsing-remitting MS (Parry et al, 2003). More targeted therapies to improve axonal mitochondrial function should be able to show energy recovering effects within days or weeks. The oral administration of fluoxetine, which is believed to stimulate glycogenolysis in astrocytes, significantly increased the NAA/Cr ratio in cerebral white matter of MS patients within 2 weeks (Mostert et al, 2006).

Possible causes of reduced axonal mitochondrial function

A number of mechanisms may lead to a reduced axonal mitochondrial energy metabolism in the normal appearing white matter of subjects with MS (Figures 3 and 4). A first mechanism may be related to nitric oxide (NO). Nitric oxide synthase (NOS2) is increased in both active focal lesions and throughout the normal appearing white matter (Broholm et al, 2004). On immunostaining, NOS2-positive cells appear to be predominantly astrocytes, and norepinephrine or other agents that elevate cAMP inhibit the expression of NOS2 in astrocytes (Feinstein, 1998; Feinstein et al, 1993). A loss of astrocytic β₂ adrenergic receptors in MS might explain why astrocytes in MS plaques and normal appearing white matter express high levels of NOS2 (De Keyser et al, 2004). Enhanced levels of NO can compete with oxygen for the binding domain on cytochrome C oxidase (complex IV in the mitochondrial respiratory chain). This may reduce the electron flow and subsequently ATP synthesis. The increased expression and activity of cytochrome C oxidase, observed in chronic lesions and normal appearing white matter of MS subjects, might represent a compensation mechanism to overcome NO occupancy of the enzyme (Mahad et al, 2009; Witte et al, 2009).

Figure 3

(A) Schematic representation of the astrocyte-axonal lactate shuttle. Glycogenolysis is mediated by glycogen phosphorylase, which is activated by cAMP-activated protein kinase A in response to neurochemical signals, such as norepinephrine (NE). Glycolysis leads to the formation of lactate, which is taken up by axons via a monocarboxylic acid transporter, and believed to be converted into pyruvate as energy substrate for mitochondrial oxidative metabolism. N-acetylaspartate (NAA) produced by axonal mitochondria is released in the extracellular space and taken up by oligodendrocytes. (B) In multiple sclerosis (MS), white-matter astrocytes are deficient in β₂ adrenergic receptors, resulting in decreased formation of cAMP and subsequently a decrease in glycogenolysis, leading to a decreased production of lactate. This causes a reduction in axonal mitochondrial metabolism as evidenced by a decreased formation of NAA. Reduction in adenosine triphosphate (ATP) supply by mitochondria will lead to failure of the axonal Na⁺/K⁺ pump, resulting in the accumulation of Na⁺ in the axoplasma and stimulation of the Na⁺/Ca²⁺ exchanger to operate in the reverse Ca²⁺ import mode. Together with an overactivation of α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionic acid (AMPA)/kainate receptors, due to enhanced extracellular glutamate levels, this will increase intraaxonal levels of Ca²⁺, which in turn will lead to an overstimulation of various Ca²⁺-dependent catabolic enzymes and mitochondrial damage. Enhanced levels of nitric oxide (NO) may contribute to mitochondrial dysfunction.

Figure 4

(A) Schematic representation of the astrocyte-axonal glutamine shuttle. Glycogenolysis is mediated by glycogen phosphorylase, which is activated by cAMP-activated protein kinase A in response to neurochemical signals, such as norepinephrine (NE). Glycogen can be degraded via glucose-6-phosphate into pyruvate, which is introduced in the tricarboxylic acid (TCA) cycle. α-Ketoglutarate can leave the TCA cycle to form glutamate that is converted to glutamine by glutamine synthetase. Glutamine is released in the extracellular space, and taken up by the axons to be used in the axonal TCA cycle (see Figure 2). N-acetylaspartate (NAA) produced by axonal mitochondria is released in the extracellular space and taken up by oligodendrocytes. (B) In multiple sclerosis (MS), white-matter astrocytes are deficient in β₂ adrenergic receptors, resulting in decreased glycogenolysis and production of glutamine. This may impair axonal mitochondrial metabolism as evidenced by a decreased formation of NAA, and lead to axonal damage by mechanisms described in Figure 3. AMPA, α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionic acid.

A second mechanism is toxicity caused by increased glutamate levels, which have been detected throughout the normal appearing white matter (Srinivasan et al, 2005). Enhanced extracellular glutamate levels might result from a reduced astrocyte energy metabolism and failure of glutamate uptake (see above). An increased influx of Ca²⁺ into axons by overstimulation of AMPA/kainate receptors (Ouardouz et al, 2009a, 2009b) may damage mitochondria by promoting Ca²⁺ entry into the matrix, opening of the permeability transition pore, and release of cytochrome C into the cytosol (Gunter et al, 2004).

A third possible mechanism is an impaired glycogenolysis caused by a deficiency of β₂ adrenergic receptors in white-matter astrocytes (De Keyser et al, 1999; Zeinstra et al, 2000). Astrocytes are the main glycogen reservoir in the central nervous system. In-vitro studies on mouse central white matter suggest that activation of astrocytic β adrenergic receptors by norepinephrine stimulates glycogenolysis to produce lactate that is released by astrocytes and is taken up by axons, where it may serve as energy source (Figure 3A; Brown et al, 2004; Brown and Ransom, 2007; Tekkok et al, 2005; Wender et al, 2000). In axons, lactate is converted to pyruvate, which is a source of acetyl CoA required for the synthesis of NAA. In isolated rat brain mitochondria, the efflux of NAA was no longer detectable in the absence of pyruvate (Patel and Clark, 1979). In MS, decreased astrocytic glycogenolysis and lactate formation may compromise axonal mitochondrial metabolism and the synthesis of NAA (Figure 3B). A contribution of astrocyte glycogenolysis in axonal mitochondrial energy metabolism in MS is supported by the finding that a short course with fluoxetine, which stimulates glycogenolysis in primary cultures of mice astrocytes (Allaman et al, 2011; Zhang et al, 1993) increased NAA levels in the centrum semiovale of MS subjects (Mostert et al, 2006).

A fourth mechanism to be considered is a reduced astrocytic oxidative metabolism and decreased astrocytic synthesis of glutamine. This would impair the glutamine shuttle as energy source for axons (Figures 2, 4A, and 4B; Hertz and Gibbs, 2009). Compared with controls, several nuclear-encoded mitochondrial genes and the functional activities of mitochondrial respiratory chain complexes I and III were decreased in motor cortex from MS patients (Dutta et al, 2006). The authors claimed that the reduced mitochondrial gene expression was specific for neurons, but this is difficult to prove since protoplasmic astrocytes in motor cortex also exhibit robust oxidative metabolism (Lovatt et al, 2007). Whether a reduced oxidative metabolism occurs in white-matter astrocytes in MS has not been studied. Compared with myelinated hippocampus and demyelinated motor cortex, demyelinated hippocampus dissected from postmortem MS brains showed a downregulation of glutamine synthetase (Dutta et al, 2011). A deficiency in white-matter astrocytic β2 adrenergic receptors and reduced glycogenolysis in MS might impair astrocytic oxidative metabolism and glutamine synthetase activity. Support for this hypothesis comes from studies showing that the addition of dibutyryl-cAMP, which is a cell permeable cAMP analog, enhanced glutamine synthetase activity in astrocyte cultures (Brookes, 1992; Stanimirovic et al, 1999).

Enhanced consumption of ATP leads to an increase in oxypurines (uric acid, hypoxanthine, and xanthine) and purine nucleosides (inosine, adenosine, and guanosine), which are ATP breakdown products. Higher cerebrospinal fluid and serum concentrations of these end products were found in MS subjects compared with controls (Amorini et al, 2009; Lazzarino et al, 2010). In a follow-up study, higher baseline ATP metabolites were associated with a more severe progression of disability and brain atrophy 3 years later, suggesting that an increased energy demand precedes the axonal degeneration in MS. Neuron-specific enolase is a critical enzyme in neuro-axonal glycolysis, where it converts 2-phospho-D glycerate to phosphoenolpyruvate. Multiple sclerosis patients with a clinically relevant progression of disability after 5 years of follow-up had lower baseline plasma neuron-specific enolase levels than those who remained clinically stable (Koch et al, 2007b), supporting the hypothesis that reduced axonal metabolic activity may precede axonal degeneration and progression of disability in MS.

Consequences of axonal energy failure

A decreased ATP production by mitochondria reduces the activity of the axolemmal Na⁺/K⁺ pump, leading to intraaxonal accumulation of Na⁺ and relative axonal depolarization. This may open voltage-gated Ca²⁺ channels and induce reversal of the Na⁺/K⁺ exchanger, leading to intraaxonal accumulation of Ca²⁺ (Figure 3). The intraaxonal Ca²⁺ overload will damage mitochondria (see above) and inappropriately stimulate a variety of Ca²⁺-dependent catabolic enzyme systems, including proteases, phospholipases, and calpains, ultimately leading to axonal degeneration (Stys, 2005). In addition, reduced formation of NAA may impair myelin membrane turnover and lead to loss of myelin. The maintenance of myelin requires a continuous and dynamic process of myelin component catabolism and recycling (Ando et al, 2003). N-acetylaspartate is transported from axons to the cytoplasm of oligodendrocytes, where aspartoacylase cleaves the acetate moiety for use in fatty acid and steroid synthesis. The fatty acids and steroids produced then go on to be used as building blocks for myelin lipid synthesis (Moffett et al, 2007). As mentioned above, axons losing their myelin sheath are prone to degeneration (Irvine and Blakemore, 2008).

Benign multiple sclerosis

It has long been recognized that a subgroup of individuals with MS shows little or no progression in severity of the disease over time. This so-called “benign MS” can be arbitrarily defined by minimal or no disability after at least 10 years of observation (Ramsaransing and De Keyser, 2006). A less axonal degenerative process appears to be present in this subset of MS patients (Gauthier et al, 2009). Compared with controls, patients with benign MS only showed a nonsignificant trend for elevated PCr ratios in the normal appearing white matter (Steen et al, 2010), and NAA levels in the normal appearing white matter were also relatively preserved (Benedetti et al, 2009; Davie et al, 1997; Steen et al, 2010). Patients with a relatively benign course of MS therefore represent an interesting subgroup to better understand compensatory mechanisms of astrocytic and axonal energy metabolism. It is not known whether patients with benign MS have less elevated glutamate levels in the normal appearing white matter. Genetic association studies may give worthwhile clues. A recent genome-wide association analysis in patients with MS found a significant association between genes with high relevance to glutamate biology and both brain glutamate levels and the degree of neurodegeneration over 1 year of follow-up (Baranzini et al, 2010). This finding needs to be confirmed, and the role of the gene products clarified.

Conclusion

Evidence is evolving that a defective axonal energy metabolism has a role in the diffuse axonal degeneration in MS. A number of findings suggest that at least part of this defective axonal metabolism might be secondary to astrocyte dysfunction. A deficiency in astrocytic β₂ adrenergic receptors may be responsible for a reduced glycogenolysis, resulting in a decreased formation of lactate and glutamine, which are energy sources for axons, and for increased levels of NO. An impaired PCr metabolism in astrocytes may lead to increased levels of glutamate in the extracellular space surrounding axons. All these mechanisms can converge to an intraaxonal Ca²⁺ overload that further impairs mitochondrial function and stimulates catabolic enzymes, leading to axonal degeneration. In addition, decreased NAA levels and excitotoxic damage of oligodendrocytes may impair axonal myelination, and contribute to axonal degeneration. A better insight into these different processes and the protective factors that underlie a relatively benign disease course might ultimately lead to new therapies that slow down the progression of disability in patients with MS.

Footnotes

Acknowledgements

Our research on the role of astrocytes in MS is supported by FWO Belgium (http://www.fwo.be) and the Belgian Charcot Foundation ().

The authors declare no conflict of interest.

References

Aboul-Enein

Krssak

Hoftberger

Prayer

Kristoferitsch

(2010) Reduced NAA-levels in the NAWM of patients with MS is a feature of progression. A study with quantitative magnetic resonance spectroscopy at 3 Tesla. PLoS One 5:e11625.

Aksenov

Aksenova

Butterfield

Markesbery

(2000) Oxidative modification of creatine kinase BB in Alzheimer's disease brain. J Neurochem 74:2520–7.

Aksenova

Aksenov

Payne

Trojanowski

Schmidt

Carney

Butterfield

Markesbery

(1999) Oxidation of cytosolic proteins and expression of creatine kinase BB in frontal lobe in different neurodegenerative disorders. Dement Geriatr Cogn Disord 10:158–65.

Alix

Domingues

(2011) White matter synapses: form, function, and dysfunction. Neurology 76:397–404.

Allaman

Fiumelli

Magistretti

Martin

(2011) Fluoxetine regulates the expression of neurotrophic/growth factors and glucose metabolism in astrocytes. Psychopharmacology 216:75–84.

Amorini

Petzold

Tavazzi

Eikelenboom

Keir

Belli

Giovannoni

Di Pietro

Polman

D'Urso

Vagnozzi

Uitdehaag

Lazzarino

(2009) Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients. Clin Biochem 42:1001–6.

Anderson

Swanson

(2000) Astrocyte glutamate transport: review of properties, regulation, and physiological functions. Glia 32:1–14.

Ando

Tanaka

Toyoda

Kon

(2003) Turnover of myelin lipids in aging brain. Neurochem Res 28:5–13.

Baranzini

Srinivasan

Khankhanian

Okuda

Nelson

Matthews

Hauser

Oksenberg

Pelletier

(2010) Genetic variation influences glutamate concentrations in brains of patients with multiple sclerosis. Brain 133:2603–11.

10.

Bates

Strangward

Keelan

Davey

Munro

Clark

(1996) Inhibition of N-acetylaspartate production: implications for 1H MRS studies in vivo. Neuroreport 7:1397–400.

11.

Benedetti

Rovaris

Rocca

Caputo

Zaffaroni

Capra

Bertolotto

Martinelli

Comi

Filippi

(2009) In-vivo evidence for stable neuroaxonal damage in the brain of patients with benign multiple sclerosis. Mult Scler 15:789–94.

12.

Bergers

Bot

De Groot

Polman

Lycklama a Nijeholt

Castelijns

Van der Valk

Barkhof

(2002) Axonal damage in the spinal cord of MS patients occurs largely independent of T2 MRI lesions. Neurology 59:1766–71.

13.

Broholm

Andersen

Wanscher

Frederiksen

Rubin

Pakkenberg

Larsson

Lauritzen

(2004) Nitric oxide synthase expression and enzymatic activity in multiple sclerosis. Acta Neurol Scand 109:261–9.

14.

Brookes

(1992) Regulation of the glutamine content of astrocytes by cAMP and hydrocortisone: effect of pH. Neurosci Lett 147:139–42.

15.

Brosnan

(2007) Creatine: endogenous metabolite, dietary, and therapeutic supplement. Annu Rev Nutr 27:241–61.

16.

Brown

Baltan Tekkok

Ransom

(2004) Energy transfer from astrocytes to axons: the role of CNS glycogen. Neurochem Int 45:529–36.

17.

Brown

Ransom

(2007) Astrocyte glycogen and brain energy metabolism. Glia 55:1263–71.

18.

Cader

Johansen-Berg

Wylezinska

Palace

Behrens

Smith

Matthews

(2007) Discordant white matter N-acetylasparate and diffusion MRI measures suggest that chronic metabolic dysfunction contributes to axonal pathology in multiple sclerosis. Neuroimage 36:19–27.

19.

Chard

Griffin

McLean

Kapeller

Kapoor

Thompson

Miller

(2002) Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. Brain 125:2342–52.

20.

Chiti

Teschemacher

(2007) Exocytosis of norepinephrine at axon varicosities and neuronal cell bodies in the rat brain. FASEB J 21:2540–50.

21.

Ciccarelli

Altmann

McLean

Wheeler-Kingshott

Wimpey

Miller

Thompson

(2010a) Spinal cord repair in MS: does mitochondrial metabolism play a role? Neurology 74:721–7.

22.

Ciccarelli

Toosy

De Stefano

Wheeler-Kingshott

Miller

Thompson

(2010b) Assessing neuronal metabolism in vivo by modeling imaging measures. J Neurosci 30:15030–3.

23.

Compston

Coles

(2008) Multiple sclerosis. Lancet 372:1502–17.

24.

Confavreux

Vukusic

(2006) Natural history of multiple sclerosis: a unifying concept. Brain 129:606–16.

25.

Danbolt

(2001) Glutamate uptake. Prog Neurobiol 65:1–105.

26.

Davie

Barker

Thompson

Tofts

McDonald

Miller

(1997) 1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis. J Neurol Neurosurg Psychiatry 63:736–42.

27.

Davie

Hawkins

Barker

Brennan

Tofts

Miller

McDonald

(1994) Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 117(Part 1):49–58.

28.

De Keyser

Mostert

Koch

(2008) Dysfunctional astrocytes as key players in the pathogenesis of central nervous system disorders. J Neurol Sci 267:3–16.

29.

De Keyser

Wilczak

Leta

Streetland

(1999) Astrocytes in multiple sclerosis lack beta-2 adrenergic receptors. Neurology 53:1628–33.

30.

De Keyser

Zeinstra

Wilczak

(2004) Astrocytic beta2-adrenergic receptors and multiple sclerosis. Neurobiol Dis 15:331–9.

31.

De Stefano

Matthews

Narayanan

Stanley

Francis

Antel

Arnold

(1998) Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain 121 (Part 8):1469–77.

32.

De Stefano

Narayanan

Francis

Arnaoutelis

Tartaglia

Antel

Matthews

Arnold

(2001) Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 58:65–70.

33.

De Stefano

Narayanan

Francis

Smith

Mortilla

Tartaglia

Bartolozzi

Guidi

Federico

Arnold

(2002) Diffuse axonal and tissue injury in patients with multiple sclerosis with low cerebral lesion load and no disability. Arch Neurol 59:1565–71.

34.

DeLuca

Williams

Evangelou

Ebers

Esiri

(2006) The contribution of demyelination to axonal loss in multiple sclerosis. Brain 129:1507–16.

35.

Domercq

Etxebarria

Perez-Samartin

Matute

(2005) Excitotoxic oligodendrocyte death and axonal damage induced by glutamate transporter inhibition. Glia 52:36–46.

36.

Domercq

Matute

(1999) Expression of glutamate transporters in the adult bovine corpus callosum. Brain Res Mol Brain Res 67:296–302.

37.

Dutta

Chang

Doud

Kidd

Ribaudo

Young

Fox

Staugaitis

Trapp

(2011) Demyelination causes synaptic alterations in hippocampi from multiple sclerosis patients. Ann Neurol 69:445–54.

38.

Dutta

McDonough

Yin

Peterson

Chang

Torres

Gudz

Macklin

Lewis

Fox

Rudick

Mirnics

Trapp

(2006) Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol 59:478–89.

39.

Evangelou

Esiri

Smith

Palace

Matthews

(2000) Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. Ann Neurol 47:391–5.

40.

Fan

Yuan

Lane

Higashi

Wang

Hamidi

Zhou

Guitart

Chen

Manji

Kaddurah-Daouk

(2010) Stable isotope-resolved metabolomic analysis of lithium effects on glial-neuronal metabolism and interactions. Metabolomics 6:165–79.

41.

Feinstein

(1998) Suppression of astroglial nitric oxide synthase expression by norepinephrine results from decreased NOS-2 promoter activity. J Neurochem 70:1484–96.

42.

Feinstein

Galea

Reis

(1993) Norepinephrine suppresses inducible nitric oxide synthase activity in rat astroglial cultures. J Neurochem 60:1945–8.

43.

Ferguson

Matyszak

Esiri

Perry

(1997) Axonal damage in acute multiple sclerosis lesions. Brain 120(Part 3):393–9.

44.

Fonseca

Monteiro

Alves

Carrondo

Santos

(2005) Cultures of rat astrocytes challenged with a steady supply of glutamate: new model to study flux distribution in the glutamate-glutamine cycle. Glia 51:286–96.

45.

Frischer

Bramow

Dal-Bianco

Lucchinetti

Rauschka

Schmidbauer

Laursen

Sorensen

Lassmann

(2009) The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 132:1175–89.

46.

Matthews

De Stefano

Worsley

Narayanan

Francis

Antel

Wolfson

Arnold

(1998) Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 121 (Part 1):103–13.

47.

Gauthier

Berger

Liptak

Duan

Egorova

Buckle

Glanz

Khoury

Bakshi

Weiner

Guttmann

(2009) Rate of brain atrophy in benign versus early multiple sclerosis. Arch Neurol 66:234–7.

48.

Geeraedts

Wilczak

Van Binnendijk

De Keyser

(2004) Search for morbillivirus proteins in multiple sclerosis brain tissue. Neuroreport 15:27–32.

49.

Graumann

Reynolds

Steck

Schaeren-Wiemers

(2003) Molecular changes in normal appearing white matter in multiple sclerosis are characteristic of neuroprotective mechanisms against hypoxic insult. Brain Pathol 13:554–73.

50.

Gunter

Yule

Gunter

Eliseev

Salter

(2004) Calcium and mitochondria. FEBS Lett 567:96–102.

51.

Hassel

(2001) Pyruvate carboxylation in neurons. J Neurosci Res 66:755–62.

52.

Hertz

Gibbs

(2009) What learning in day-old chickens can teach a neurochemist: focus on astrocyte metabolism. J Neurochem 109(Suppl 1):10–6.

53.

Hertz

Peng

Dienel

(2007) Energy metabolism in astrocytes: high rate of oxidative metabolism and spatiotemporal dependence on glycolysis/glycogenolysis. J Cereb Blood Flow Metab 27:219–49.

54.

Husted

Goodin

Hugg

Maudsley

Tsuruda

De Bie

Fein

Matson

Weiner

(1994) Biochemical alterations in multiple sclerosis lesions and normal-appearing white matter detected by in vivo 31P and 1H spectroscopic imaging. Ann Neurol 36:157–65.

55.

Irvine

Blakemore

(2008) Remyelination protects axons from demyelination-associated axon degeneration. Brain 131:1464–77.

56.

Karadottir

Attwell

(2007) Neurotransmitter receptors in the life and death of oligodendrocytes. Neuroscience 145:1426–38.

57.

Khan

Shen

Caon

Bao

Ching

Reznar

Buccheister

Latif

Tselis

Lisak

(2005) Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult Scler 11:646–51.

58.

Kimelberg

Nedergaard

(2010) Functions of astrocytes and their potential as therapeutic targets. Neurotherapeutics 7:338–53.

59.

Koch

Mostert

Heersema

De Keyser

(2007a) Progression in multiple sclerosis: further evidence of an age dependent process. J Neurol Sci 255:35–41.

60.

Koch

Mostert

Heersema

Teelken

De Keyser

(2007b) Plasma S100beta and NSE levels and progression in multiple sclerosis. J Neurol Sci 252:154–8.

61.

Kukley

Capetillo-Zarate

Dietrich

(2007) Vesicular glutamate release from axons in white matter. Nat Neurosci 10:311–20.

62.

Kutzelnigg

Lucchinetti

Stadelmann

Bruck

Rauschka

Bergmann

Schmidbauer

Parisi

Lassmann

(2005) Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128:2705–12.

63.

Kuzhikandathil

Molloy

(1994) Transcription of the brain creatine kinase gene in glial cells is modulated by cyclic AMP-dependent protein kinase. J Neurosci Res 39:70–82.

64.

Kuzhikandathil

Molloy

(1999) Proximal promoter of the rat brain creatine kinase gene lacks a consensus CRE element but is essential for the cAMP-mediated increased transcription in glioblastoma cells. J Neurosci Res 56:371–85.

65.

Langemann

Kabiersch

Newcombe

(1992) Measurement of low-molecular-weight antioxidants, uric acid, tyrosine and tryptophan in plaques and white matter from patients with multiple sclerosis. Eur Neurol 32:248–52.

66.

Lassmann

Reindl

Rauschka

Berger

Aboul-Enein

Berger

Zurbriggen

Lutterotti

Bruck

Weber

Ullrich

Schmidbauer

Jellinger

Vandevelde

(2003) A new paraclinical CSF marker for hypoxialike tissue damage in multiple sclerosis lesions. Brain 126:1347–57.

67.

Lazzarino

Amorini

Eikelenboom

Killestein

Belli

Di Pietro

Tavazzi

Barkhof

Polman

Uitdehaag

Petzold

(2010) Cerebrospinal fluid ATP metabolites in multiple sclerosis. Mult Scler 16:549–54.

68.

Leary

Davie

Parker

Stevenson

Wang

Barker

Miller

Thompson

(1999) 1H magnetic resonance spectroscopy of normal appearing white matter in primary progressive multiple sclerosis. J Neurol 246:1023–6.

69.

Lee

Blamire

Pendlebury

Mills

Styles

Palace

Matthews

(2000) Axonal injury or loss in the internal capsule and motor impairment in multiple sclerosis. Arch Neurol 57:65–70.

70.

Lovatt

Sonnewald

Waagepetersen

Schousboe

Lin

Han

Takano

Wang

Sim

Goldman

Nedergaard

(2007) The transcriptome and metabolic gene signature of protoplasmic astrocytes in the adult murine cortex. J Neurosci 27:12255–66.

71.

Mahad

Ziabreva

Campbell

Lax

White

Hanson

Lassmann

Turnbull

(2009) Mitochondrial changes within axons in multiple sclerosis. Brain 132:1161–74.

72.

Metz

Lucchinetti

Openshaw

Garcia-Merino

Lassmann

Freedman

Atkins

Azzarelli

Kolar

Bruck

(2007) Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis. Brain 130:1254–62.

73.

Minderhoud

Mooyaart

Kamman

Teelken

Hoogstraten

Vencken

Gravenmade

Van den Burg

(1992) In vivo phosphorus magnetic resonance spectroscopy in multiple sclerosis. Arch Neurol 49:161–5.

74.

Moffett

Ross

Arun

Madhavarao

Namboodiri

(2007) N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol 81:89–131.

75.

Mostert

Sijens

Oudkerk

De Keyser

(2006) Fluoxetine increases cerebral white matter NAA/Cr ratio in patients with multiple sclerosis. Neurosci Lett 402:22–4.

76.

Narayanan

De Stefano

Francis

Arnaoutelis

Caramanos

Collins

Pelletier

Arnason

BGW

Antel

Arnold

(2001) Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol 248:979–86.

77.

Nave

(2010) Myelination and the trophic support of long axons. Nat Rev Neurosci 11:275–83.

78.

Ouardouz

Coderre

Basak

Chen

Zamponi

Hameed

Rehak

Yin

Trapp

Stys

(2009a) Glutamate receptors on myelinated spinal cord axons: I. GluR6 kainate receptors. Ann Neurol 65:151–9.

79.

Ouardouz

Coderre

Zamponi

Hameed

Yin

Trapp

Stys

(2009b) Glutamate receptors on myelinated spinal cord axons: II. AMPA and GluR5 receptors. Ann Neurol 65:160–6.

80.

Parry

Corkill

Blamire

Palace

Narayanan

Arnold

Styles

Matthews

(2003) Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis. J Neurol 250:171–8.

81.

Patel

Clark

(1979) Synthesis of N-acetyl-l-aspartate by rat brain mitochondria and its involvement in mitochondrial/cytosolic carbon transport. Biochem J 184:539–46.

82.

Raine

(1984) On the association between perinodal astrocytic processes and the node of Ranvier in the C.N.S. J Neurocytol 13:21–7.

83.

Ramsaransing

De Keyser

(2006) Benign course in multiple sclerosis: a review. Acta Neurol Scand 113:359–69.

84.

Ransom

Behar

Nedergaard

(2003) New roles for astrocytes (stars at last). Trends Neurosci 26:520–2.

85.

Reichenbach

Derouiche

Kirchhoff

(2010) Morphology and dynamics of perisynaptic glia. Brain Res Rev 63:11–25.

86.

Rose

Koo

Antflick

Ahmed

Angers

Hampson

(2009) Glutamate transporter coupling to Na,K-ATPase. J Neurosci 29:8143–55.

87.

Salter

Fern

(2005) NMDA receptors are expressed in developing oligodendrocyte processes and mediate injury. Nature 438:1167–71.

88.

Sarchielli

Greco

Floridi

Gallai

(2003) Excitatory amino acids and multiple sclerosis: evidence from cerebrospinal fluid. Arch Neurol 60:1082–8.

89.

Seehusen

Baumgartner

(2010) Axonal pathology and loss precede demyelination and accompany chronic lesions in a spontaneously occurring animal model of multiple sclerosis. Brain Pathol 20:551–9.

90.

Silver

Erecinska

(1997) Energetic demands of the Na+/K+ ATPase in mammalian astrocytes. Glia 21:35–45.

91.

Sonnewald

Westergaard

Schousboe

(1997) Glutamate transport and metabolism in astrocytes. Glia 21:56–63.

92.

Srinivasan

Sailasuta

Hurd

Nelson

Pelletier

(2005) Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain 128:1016–25.

93.

Stanimirovic

Ball

Small

Muruganandam

(1999) Developmental regulation of glutamate transporters and glutamine synthetase activity in astrocyte cultures differentiated in vitro. Int J Dev Neurosci 17:173–84.

94.

Steen

Wilczak

Hoogduin

Koch

De Keyser

(2010) Reduced creatine kinase B activity in multiple sclerosis normal appearing white matter. PLoS One 5:e10811.

95.

Stys

(2005) General mechanisms of axonal damage and its prevention. J Neurol Sci 233:3–13.

96.

Banker

Bourdette

Forte

(2009) Axonal degeneration in multiple sclerosis: the mitochondrial hypothesis. Curr Neurol Neurosci Rep 9:411–7.

97.

Tachikawa

Fukaya

Terasaki

Ohtsuki

Watanabe

(2004) Distinct cellular expressions of creatine synthetic enzyme GAMT and creatine kinases uCK-Mi and CK-B suggest a novel neuron-glial relationship for brain energy homeostasis. Eur J Neurosci 20:144–60.

98.

Tekkok

Brown

Westenbroek

Pellerin

Ransom

(2005) Transfer of glycogen-derived lactate from astrocytes to axons via specific monocarboxylate transporters supports mouse optic nerve activity. J Neurosci Res 81:644–52.

99.

Thompson

Kynoch

Sarjant

(1980) Immunohistochemical localization of creatine kinase-BB isoenzyme to astrocytes in human brain. Brain Res 201:423–6.

100.

Tiberio

Chard

Altmann

Davies

Griffin

McLean

Rashid

Sastre-Garriga

Thompson

Miller

(2006) Metabolite changes in early relapsing-remitting multiple sclerosis. A two year follow-up study. J Neurol 253:224–30.

101.

Trapp

Peterson

Ransohoff

Rudick

Mork

(1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338:278–85.

102.

Trapp

Stys

(2009) Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol 8:280–91.

103.

Vallejo-Illarramendi

Domercq

Perez-Cerda

Ravid

Matute

(2006) Increased expression and function of glutamate transporters in multiple sclerosis. Neurobiol Dis 21:154–64.

104.

Van der Knaap

Pouwels

PJW

(2005) Magnetic resonance spectroscopy: basic principles and application in white matter disorders. In: Magnetic resonance of myelination and myelin disorders ( Van der Knaap

Valk

, eds). Berlin: Springer, 859–80.

105.

Vandevelde

Zurbriggen

(2005) Demyelination in canine distemper virus infection: a review. Acta Neuropathol 109:56–68.

106.

Wender

Brown

Fern

Swanson

Farrell

Ransom

(2000) Astrocytic glycogen influences axon function and survival during glucose deprivation in central white matter. J Neurosci 20:6804–10.

107.

Wilkins

Scolding

(2008) Protecting axons in multiple sclerosis. Mult Scler 14:1013–25.

108.

Witte

Rodenburg

Belien

Musters

Hazes

Wintjes

Smeitink

Geurts

De Vries

Van der Valk

Van Horssen

(2009) Enhanced number and activity of mitochondria in multiple sclerosis lesions. J Pathol 219:193–204.

109.

Wolosker

Panizzutti

Engelender

(1996) Inhibition of creatine kinase by S-nitrosoglutathione. FEBS Lett 392:274–6.

110.

Liu

Hughes

McAdoo

(2008) Glutamate-induced losses of oligodendrocytes and neurons and activation of caspase-3 in the rat spinal cord. Neuroscience 153:1034–47.

111.

Yudkoff

Nelson

Daikhin

Erecinska

(1994) Tricarboxylic acid cycle in rat brain synaptosomes. Fluxes and interactions with aspartate aminotransferase and malate/aspartate shuttle. J Biol Chem 269:27414–20.

112.

Zeinstra

Wilczak

De Keyser

(2000) [3H]dihydroalprenolol binding to beta adrenergic receptors in multiple sclerosis brain. Neurosci Lett 289:75–7.

113.

Zhang

Peng

Chen

Hertz

(1993) Stimulation of glycogenolysis in astrocytes by fluoxetine, an antidepressant acting like 5-HT. Neuroreport 4:1235–8.

114.

Ziskin

Nishiyama

Rubio

Fukaya

Bergles

(2007) Vesicular release of glutamate from unmyelinated axons in white matter. Nat Neurosci 10:321–30.